Literature DB >> 26922962

[Autism spectrum disorder and epilepsy: the role of ketogenic diet].

J J Garcia-Penas1.   

Abstract

INTRODUCTION: Between 5-40% of autistic patients will develop epilepsy. Most individuals with autism and epilepsy will respond to pharmacologic treatment; however, approximately 20-30% will develop medically refractory epilepsy. For this population, alternative treatments such as ketogenic diet (KD) can be highly efficacious and should be seriously considered. AIM: To discuss the use of the KD in refractory pediatric epilepsy and its role in patients with autism and epilepsy. DEVELOPMENT: KD is an effective and well-tolerated treatment for refractory childhood epilepsy, including those patients who associate autism and epilepsy. Accurate characterization of the electroclinical epilepsy syndrome is the key to deciding when to consider the KD. Otherwise, the positive effect of KD for treating mitochondrial oxidative disorders and different models of autistic animals suggest that KD could be a good alternative treatment for autistic patients.
CONCLUSIONS: Based on the demonstrated efficacy of KD in patients who associate both epilepsy and autism, KD treatment has been recently used in the treatment of autism spectrum disorders; however, there is lacking of controlled studies to define the real efficacy of this therapy. A well designed randomized controlled study is needed to determine whether KD is really efficacious for these patients.

Entities:  

Mesh:

Year:  2016        PMID: 26922962

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Preclinical testing of the ketogenic diet in fragile X mice.

Authors:  Pamela R Westmark; Alejandra Gutierrez; Aaron K Gholston; Taralyn M Wilmer; Cara J Westmark
Journal:  Neurochem Int       Date:  2020-01-17       Impact factor: 3.921

Review 2.  The Current Status of the Ketogenic Diet in Psychiatry.

Authors:  Emmanuelle C S Bostock; Kenneth C Kirkby; Bruce V M Taylor
Journal:  Front Psychiatry       Date:  2017-03-20       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.